Eli Lilly's bid for approval for an experimental weight-loss pill got a boost on Wednesday with new clinical trial data, and ...

Delve into Eli Lilly’s biopharma strategy as it advances its pipeline, wins regulatory milestones, and forges strategic deals ...

Tribeca Studios has launched a new incubator program, which aims to empower rising filmmakers to more earnestly portray diseases and health-related stories on-screen. Tribeca created the program with ...

Eli Lilly has developed artificial intelligence models that can help predict the behavior of potential drug candidates, based on the data the drugmaker has collected over the last two decades and at ...

"I had two pandemic seasons ... half the writer's room of everyone else and half the budget," the YouTuber and TV host explains.

Discover why LLY stock is rated Buy as sales surge in diabetes & obesity drugs and new treatments drive future growth.

Purdue University offers a wide variety of online and hybrid programs that are eligible for education benefits through EdAssist by Bright Horizons. Use this program finder to browse eligible programs ...

A federal appeals court on Thursday rejected Eli Lilly’s appeal of an $183.7 million judgment won by a whistleblowing lawyer and pharmacist who accused the drugmaker of defrauding Medicaid. The 7th ...

Model Lily Aldridge talks cozy glamour, family rituals and how her new capsule collection with Eberjey brings beauty to even ...

In the latest close session, Eli Lilly (LLY) was up +1.51% at $738.17. The stock outpaced the S&P 500's daily gain of 0.21%. Elsewhere, the Dow gained 0.25%, while the tech-heavy Nasdaq added 0.45%.

I am bullish on Eli Lilly, despite recent underperformance and Orforglipron's clinical results falling short of high expectations. Eli Lilly's robust R&D, strong pipeline, and leadership in diabetes, ...